Compare Stocks: ENLV, KYNB, ATOS, and TCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.39 -2.3%	$2.40	$1.70 ▼ $17.25	$23.80M	1.27	116,267 shs	71,416 shs
ENLV Enlivex Therapeutics	$0.26 +1.2%	$1.14	$0.22 ▼ $27.15	$4.49M	1.42	352,067 shs	675,398 shs
KYNB Kyntra Bio	$6.02 -1.5%	$7.30	$5.62 ▼ $11.65	$24.38M	1.05	23,020 shs	13,842 shs
TCRX TScan Therapeutics	$0.24 +2.5%	$0.52	$0.22 ▼ $2.57	$16.54M	1.15	744,376 shs	290,992 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	0.00%	+4.27%	-2.79%	+1.67%	-84.94%
ENLV Enlivex Therapeutics	0.00%	-34.42%	-73.53%	-96.19%	-98.53%
KYNB Kyntra Bio	0.00%	-3.17%	-23.34%	-16.76%	+610,999,900.00%
TCRX TScan Therapeutics	0.00%	-25.74%	-25.72%	-76.89%	-89.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.39 -2.3%	$2.40	$1.70 ▼ $17.25	$23.80M	1.27	116,267 shs	71,416 shs
ENLV Enlivex Therapeutics	$0.26 +1.2%	$1.14	$0.22 ▼ $27.15	$4.49M	1.42	352,067 shs	675,398 shs
KYNB Kyntra Bio	$6.02 -1.5%	$7.30	$5.62 ▼ $11.65	$24.38M	1.05	23,020 shs	13,842 shs
TCRX TScan Therapeutics	$0.24 +2.5%	$0.52	$0.22 ▼ $2.57	$16.54M	1.15	744,376 shs	290,992 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	0.00%	+4.27%	-2.79%	+1.67%	-84.94%
ENLV Enlivex Therapeutics	0.00%	-34.42%	-73.53%	-96.19%	-98.53%
KYNB Kyntra Bio	0.00%	-3.17%	-23.34%	-16.76%	+610,999,900.00%
TCRX TScan Therapeutics	0.00%	-25.74%	-25.72%	-76.89%	-89.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	2.20	Hold	$20.33	752.55% Upside
ENLV Enlivex Therapeutics	2.00	Hold	$247.50	96,203.50% Upside
KYNB Kyntra Bio	2.50	Moderate Buy	$37.25	518.77% Upside
TCRX TScan Therapeutics	2.13	Hold	$2.67	992.90% Upside

Current Analyst Ratings Breakdown

Latest ENLV, KYNB, ATOS, and TCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	KYNB Kyntra Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
10/2/2026	ENLV Enlivex Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/22/2026	ENLV Enlivex Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$41.00
9/17/2026	KYNB Kyntra Bio	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$41.00
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/8/2026	TCRX TScan Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$1.00
9/2/2026	TCRX TScan Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/1/2026	KYNB Kyntra Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$43.00

(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$122.21 per share	N/A
KYNB Kyntra Bio	$6.44M	3.79	N/A	N/A	($4.20) per share	-1.43
TCRX TScan Therapeutics	$10.32M	1.60	N/A	N/A	$2.16 per share	0.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
ENLV Enlivex Therapeutics	$1.24B	-$8.25	N/A	N/A	N/A	N/A	N/A	N/A	11/13/2026 (Estimated)
KYNB Kyntra Bio	$183.45M	$45.30	0.13	N/A	N/A	2,199.13%	N/A	-47.27%	N/A
TCRX TScan Therapeutics	-$129.77M	-$0.91	N/A	N/A	N/A	-1,655.35%	-108.72%	-54.47%	11/11/2026 (Estimated)

Latest ENLV, KYNB, ATOS, and TCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2026	Q2 2026	TCRX TScan Therapeutics	-$0.2534	-$0.23	+$0.0234	-$0.23	$1.88 million	$1.05 million
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
KYNB Kyntra Bio	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	5.69	5.69
ENLV Enlivex Therapeutics	N/A	119.39	119.39
KYNB Kyntra Bio	N/A	2.69	2.59
TCRX TScan Therapeutics	0.31	3.37	3.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
ENLV Enlivex Therapeutics	1.02%
KYNB Kyntra Bio	72.71%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	9.80%
ENLV Enlivex Therapeutics	12.28%
KYNB Kyntra Bio	4.15%
TCRX TScan Therapeutics	6.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
ENLV Enlivex Therapeutics	34	17.49 million	15.34 million	Optionable
KYNB Kyntra Bio	570	4.05 million	3.88 million	N/A
TCRX TScan Therapeutics	142	67.78 million	63.54 million	Not Optionable

ENLV, KYNB, ATOS, and TCRX Headlines

Recent News About These Companies

TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Consensus Price Target of $2.67

October 2, 2026 | americanbankingnews.com

TScan Therapeutics (NASDAQ:TCRX) Stock Jumps 1% - Here's What Happened

October 2, 2026 | americanbankingnews.com

Korro Bio (NASDAQ:KRRO) & TScan Therapeutics (NASDAQ:TCRX) Financial Review

October 1, 2026 | americanbankingnews.com

TScan Therapeutics consensus price target decreased by 55.56% to $2.72

September 16, 2026 | msn.com

Wedbush downgrades TScan Therapeutics (TCRX) to neutral from outperform

September 3, 2026 | msn.com

TScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%

September 2, 2026 | rttnews.com

TScan Therapeutics cuts workforce by 75% and shifts focus to solid tumor program

September 2, 2026 | msn.com

TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

September 2, 2026 | benzinga.com

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

September 2, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)

August 13, 2026 | theglobeandmail.com

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

August 12, 2026 | zacks.com

TScan Therapeutics Reports First Patient Dosed in Phase 3 ALLOHA-2 Study and Second-Quarter 2026 Results

August 12, 2026 | quiverquant.comQ

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | globenewswire.com

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 29, 2026 | globenewswire.com

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 24, 2026 | globenewswire.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...

June 23, 2026 | markets.businessinsider.com

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

June 22, 2026 | globenewswire.com

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

June 3, 2026 | businesswire.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

June 2, 2026 | insidermonkey.com

TScan Therapeutics Expands Authorized Shares After Stockholder Vote

May 22, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ENLV, KYNB, ATOS, and TCRX Company Descriptions

Atossa Genetics NASDAQ:ATOS

$2.38 -0.06 (-2.25%)

As of 01:59 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Enlivex Therapeutics NASDAQ:ENLV

$0.26 +0.00 (+1.18%)

As of 02:02 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Kyntra Bio NASDAQ:KYNB

$6.02 -0.09 (-1.47%)

As of 02:01 PM Eastern

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

TScan Therapeutics NASDAQ:TCRX

$0.24 +0.01 (+2.52%)

As of 01:58 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, KYNB, ATOS, and TCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, KYNB, ATOS, and TCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, KYNB, ATOS, and TCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENLV, KYNB, ATOS, and TCRX Company Descriptions

Atossa Genetics NASDAQ:ATOS

Enlivex Therapeutics NASDAQ:ENLV

Kyntra Bio NASDAQ:KYNB

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENLV, KYNB, ATOS, and TCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENLV, KYNB, ATOS, and TCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENLV, KYNB, ATOS, and TCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ENLV, KYNB, ATOS, and TCRX Company Descriptions

Atossa Genetics NASDAQ:ATOS

Enlivex Therapeutics NASDAQ:ENLV

Kyntra Bio NASDAQ:KYNB

TScan Therapeutics NASDAQ:TCRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools